Idioma:

Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation

Gu, Sean X ; Tyagi, Tarun ; Jain, Kanika ; Gu, Vivian W ; Lee, Seung Hee ; Hwa, Jonathan M ; Kwan, Jennifer M ; Krause, Diane S ; Lee, Alfred I ; Halene, Stephanie ; Martin, Kathleen A ; Chun, Hyung J ; Hwa, John

Nature reviews cardiology, 2021-03, Vol.18 (3), p.194-209 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation
Autor: Gu, Sean X ; Tyagi, Tarun ; Jain, Kanika ; Gu, Vivian W ; Lee, Seung Hee ; Hwa, Jonathan M ; Kwan, Jennifer M ; Krause, Diane S ; Lee, Alfred I ; Halene, Stephanie ; Martin, Kathleen A ; Chun, Hyung J ; Hwa, John
Assuntos: Administration, Inhalation ; Anticoagulants - therapeutic use ; Blood clot ; Blood clotting disorders ; Blood Coagulation Disorders - blood ; Blood Coagulation Disorders - drug therapy ; Blood Coagulation Disorders - etiology ; Blood Coagulation Disorders - physiopathology ; Blood Platelet Disorders - blood ; Blood Platelet Disorders - drug therapy ; Blood Platelet Disorders - etiology ; Blood Platelet Disorders - physiopathology ; Care and treatment ; Coronaviruses ; COVID-19 ; COVID-19 - blood ; COVID-19 - complications ; COVID-19 - physiopathology ; COVID-19 Drug Treatment ; Development and progression ; Endothelium, Vascular - physiopathology ; Endothelium-Dependent Relaxing Factors - therapeutic use ; Epoprostenol - therapeutic use ; Heart Disease Risk Factors ; Humans ; Iloprost - therapeutic use ; Inflammation ; Inflammation - blood ; Inflammation - etiology ; Inflammation - physiopathology ; Nitric Oxide - therapeutic use ; Pathogenesis ; Pathology ; Platelet Aggregation Inhibitors - therapeutic use ; Review ; Risk factors ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Systemic Inflammatory Response Syndrome - blood ; Systemic Inflammatory Response Syndrome - drug therapy ; Systemic Inflammatory Response Syndrome - physiopathology ; Thrombosis ; Thrombosis - blood ; Thrombosis - etiology ; Thrombosis - immunology ; Thrombotic Microangiopathies - blood ; Thrombotic Microangiopathies - drug therapy ; Thrombotic Microangiopathies - etiology ; Thrombotic Microangiopathies - physiopathology ; Vascular Diseases - blood ; Vascular Diseases - drug therapy ; Vascular Diseases - etiology ; Vascular Diseases - physiopathology ; Vasodilator Agents - therapeutic use ; Venous Thromboembolism - blood ; Venous Thromboembolism - drug therapy ; Venous Thromboembolism - etiology ; Venous Thromboembolism - physiopathology
É parte de: Nature reviews cardiology, 2021-03, Vol.18 (3), p.194-209
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
Descrição: The core pathology of coronavirus disease 2019 (COVID-19) is infection of airway cells by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that results in excessive inflammation and respiratory disease, with cytokine storm and acute respiratory distress syndrome implicated in the most severe cases. Thrombotic complications are a major cause of morbidity and mortality in patients with COVID-19. Patients with pre-existing cardiovascular disease and/or traditional cardiovascular risk factors, including obesity, diabetes mellitus, hypertension and advanced age, are at the highest risk of death from COVID-19. In this Review, we summarize new lines of evidence that point to both platelet and endothelial dysfunction as essential components of COVID-19 pathology and describe the mechanisms that might account for the contribution of cardiovascular risk factors to the most severe outcomes in COVID-19. We highlight the distinct contributions of coagulopathy, thrombocytopathy and endotheliopathy to the pathogenesis of COVID-19 and discuss potential therapeutic strategies in the management of patients with COVD-19. Harnessing the expertise of the biomedical and clinical communities is imperative to expand the available therapeutics beyond anticoagulants and to target both thrombocytopathy and endotheliopathy. Only with such collaborative efforts can we better prepare for further waves and for future coronavirus-related pandemics.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 7 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation

Gu, Sean X ; Tyagi, Tarun ; Jain, Kanika ; Gu, Vivian W ; Lee, Seung Hee ; Hwa, Jonathan M ; Kwan, Jennifer M ; Krause, Diane S ; Lee, Alfred I ; Halene, Stephanie ; Martin, Kathleen A ; Chun, Hyung J ; Hwa, John

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.